Author: Eric P. Baron, Philippe Lucas, Joshua Eades & Olivia Hogue Published in The Journal of Headache and Pain May 2018 Abstract Background Medicinal cannabis registries typically report pain as the…
Author: Eduardo Orrego-González, Luisa Londoño-Tobón, José Ardila-González, Diego Polania-Tovar, Ana Valencia-Cárdenas and Alberto Velez-Van Meerbeke Published in Hindawi July 2020 Abstract Objectives Colorectal cancer represents a heavy burden for health systems…
Author: Eric P. Baron DO Published in HEADACHE Journal of Headache and face pain August 2018 Abstract Background Comprehensive literature reviews of historical perspectives and evidence supporting cannabis/cannabinoids in the treatment…
Authors: Giovanni Appendino, Simon Gibbons, Anna Giana, Alberto Pagani, Gianpaolo Grassi, Michael Stavri, Eileen Smith,and M. Mukhlesur Rahman Published in Journal of Natural Products August 2008 Abstract Marijuana (Cannabis sativa) has…
Authors: James Siklos-Whillans, Alia Bacchus, Laurie A. Manwell Published in International Journal of Mental Health and Addiction March 2020 Abstract Cannabis as a harm reduction strategy (HRS) is supported by evidence…
Authors: María Fernández-Trapero, Carmen Pérez-Díaz, Francisco Espejo-Porras, Eva de Lago, Javier Fernández-Ruiz Published in Biomolecules February 2020 Abstract The phytocannabinoid-based medicine Sativex® is currently marketed for the treatment of spasticity and…
Authors: Alex Mabou Tagne, Barbara Pacchetti, Mikael Sodergren, Marco Cosentino, and Franca Marino Published in Mary Ann Liebert, Inc Publishers June 2020 Abstract Background: The possibility of cannabidiol (CBD) to be…
Authors: Cathay Davies, Robin Wilson, Elizabeth Appiah-Kusi, Michael Brammer, Jesus Perez, Robin Murray, Paul Allen, Matthijas Bossong, Philip McGuire and Sagnik Bhattacharyya Published in Schizophrenia Bulletin May 2020 Abstract…
Authors: Nicholas Dopkins, Kiesha Wilson, Kathryn Miranda, Prakash S Nagarkatti and Mitzi Nagarkatti Published in The Journal of Immunology May 2020 Abstract Cannabidiol (CBD) is a nonpsychoactive ingredient from…
Authors: Sy Atezaz Saeed, MD, MS, and Kathryn E. Clary, BA Published in Current Psychiatry June 2020 Introduction There has been increasing interest in the medicinal use of cannabidiol…
Authors: Shannon Rush, Arvinder K Kapur, Manish S. Patankar, Lisa Marie Barroilhet Published in Journal of Clinical Oncology May 2020 Abstract Background: Cancer patients use cannabidiol (CBD) for chemotherapy…
Expert Opinion on Drug Metabolism & Toxicology, 9 April 2020
—
Introduction: Recent trials using cannabidiol (CBD) have shown that most acute and prolonged adverse effects of CBD are mild to moderate, with rare serious adverse effects (SAEs). This review focused on analyzing SAEs of CBD and their possible relation to drug-drug interaction…